SCHEMBL684362

SCHEMBL684362

Cn1c(=O)c2c(ncn2CN2CCN(c3ccc(F)cc3)CC2)n(C)c1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.71
HTR7 P34969 1/20 0.61
HTR6 P50406 1/20 0.61
HTR1A P08908 2/20 0.58
CHRM1 P11229 2/20 0.58
DRD2 P14416 2/20 0.58
ADRA1D P25100 2/20 0.58
ADRA1A P35348 2/20 0.58
ADRA1B P35368 2/20 0.58
RXFP1 Q9HBX9 3/20 0.57
L3MBTL1 Q9Y468 3/20 0.56
SMN1; SMN2 Q16637 4/20 0.55
TSHR P16473 4/20 0.55
HSD17B10 Q99714 3/20 0.55
ALDH1A1 P00352 2/20 0.54
CASP1 P29466 2/20 0.54
CASP7 P55210 2/20 0.54
MAPT P10636 1/20 0.53
MAOB P27338 1/20 0.53
ALOX15 P16050 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL682813 0.90 HTR7 (0.62) RAB9AHTR7HTR6RXFP1L3MBTL1
SCHEMBL11155310 0.89 HTR7 (0.74) RAB9AHTR7HTR6HTR1ACHRM1
SCHEMBL682817 0.89 LMNA (0.62) RAB9AHTR7HTR6DRD2RXFP1
SCHEMBL683655 0.89 HTR7 (0.77) RAB9AHTR7HTR6HTR1ARXFP1
SCHEMBL684028 0.88 HTR7 (0.58) RAB9AHTR7HTR6HTR1ACHRM1
SCHEMBL683604 0.87 RXFP1 (0.62) RAB9AHTR7HTR6RXFP1L3MBTL1
SCHEMBL684041 0.86 HTR7 (0.58) RAB9AHTR7HTR6RXFP1L3MBTL1
SCHEMBL683998 0.85 HTR7 (0.57) RAB9AHTR7HTR6RXFP1L3MBTL1
SCHEMBL684027 0.84 SMN1; SMN2 (0.60) RAB9AHTR7HTR6RXFP1L3MBTL1
SCHEMBL683995 0.82 MAPK1 (0.72) HTR7HTR6HTR1AL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF RAB9A 2603/4885HTR7 1398/4885HTR6 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.